SREBF1 and cancer: Sestrin2 inhibited mTORC1-mediated activation of sterol regulatory element-binding transcription factor 1 (SREBP1)/fatty acid synthase (FAS) pathway to attenuated lipogenesis and also enhanced fatty acid oxidation in energy-depleted cancer cells [20].